Molecular and Cellular Mechanisms of the In-stent-thrombosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00652015|
Recruitment Status : Withdrawn (Recruitment numbers could not at all been achieved in an acceptable period of time)
First Posted : April 3, 2008
Last Update Posted : September 23, 2015
|Condition or disease|
|Patients With SAT or LT After Stent Implantation (PCI)|
In this prospective, open, not-randomized, controlled single-center pilot study 80 patients having had an in-stent-thrombosis (40 sub-acute thromboses (SAT), 40 late thromboses (LT)) and a control group of 80 patients having not developed a thrombosis will be compared.
The aim of this study is the establishment of diagnostic markers vor prediction of SAT (detection of CD39- and CD73-activity, respectively)and of LT (EPC-number and function, respectively) correspondingly aiming at the early identification of patients with high risk for developing an in-stent-thrombosis.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Molecular and Cellular Mechanisms of the In-stent-thrombosis. Is it Possible to Predict a In-stent-thrombosis Using Biomarkers?|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
- The aim of this study is to establish diagnostic markers for prediction of SAT and LT, respectively, by identification of CD39 and CD73-activity and EPC-number and function, respectively. [ Time Frame: may 08 to may 2010 ]
Biospecimen Retention: Samples Without DNA
1 sample of approximately 30 mL blood will be taken from each patient of both study group.
CD39 and CD73 activity as well as EPC-number and function will be analyzed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652015
|RWTH University Hospital|
|Aachen, Germany, 52057|
|Principal Investigator:||Burcin Özüyaman, MD||RWTH Aachen University|